Chronic vasodilator therapy with flosequinan in <font color="red">congestive_2</font> <font color="red">heart_2</font> <font color="red">failure_2</font> <font color="red">._2</font> 
<br>
<br> This study was conducted to determine the long - term effect of flosequinan , a new orally administered arterial and venous dilator , on the clinical course of <font color="red">patients_5</font> <font color="red">with_5</font> <font color="red">moderate_5</font> <font color="red">to_5</font> <font color="red">severe_5</font> <font color="red">congestive_5</font> <font color="red">heart_5</font> <font color="red">failure_5</font> <font color="red">._5</font> <font color="red">Seventeen_6</font> <font color="red">patients_6</font> <font color="red">on_6</font> <font color="red">chronic_6</font> <font color="red">digitalis_6</font> <font color="red">and_6</font> <font color="red">diuretic_6</font> <font color="red">therapy_6</font> were randomized to receive either flosequinan ( n = 9 ) or placebo ( n = 8) in a double - blind fashion . Changes in symptomatology , exercise performance , and left ventricular function were assessed serially during the <font color="red">two_1</font> <font color="red">-_1</font> <font color="red">month_1</font> <font color="red">treatment_1</font> <font color="red">period_1</font> <font color="red">._1</font> During the course of therapy , a modest improvement in the symptom scores and functional classification of the <font color="red">flosequinan_2</font> <font color="red">-_2</font> <font color="red">treated_2</font> <font color="red">patients_2</font> was observed . Flosequinan evoked a significant increase in maximal exercise capacity . While long - term flosequinan administration also effected a progressive increase in resting heart rate , it did not consistently improve indices of left ventricular systolic function . The addition of chronic vasodilator therapy with flosequinan to standard digitalis - diuretic regimens is capable of inducing clinical improvement in <font color="red">patients_3</font> <font color="red">with_2</font> <font color="red">moderate_2</font> <font color="red">to_2</font> <font color="red">severe_2</font> <font color="red">chronic_2</font> <font color="red">heart_2</font> <font color="red">failure_2</font> <font color="red">._2</font> Trials involving larger <font color="red">patient_1</font> <font color="red">populations_1</font> will be necessary to confirm the results of this preliminary study and to determine the extent of clinical improvement , subpopulations benefited , role in heart failure therapeutics , and so forth .